OncoTTab

OncoTTab is a biotechnology company focused on the development of novel diagnostic and therapeutic products for the management of cancer. The company's core technology centers on a proprietary antibody, TAB004, which specifically targets a tumor-associated form of the Mucin 1 protein (tMUC1) found in over 80% of all cancers. OncoTTab has commercialized the Agkura Personal Lab Test, a blood-based diagnostic for monitoring breast cancer recurrence and treatment response. Additionally, the company is exploring therapeutic applications of its tMUC1-targeting platform, including antibody-drug conjugates and CAR-T therapies. The company was spun out of the University of North Carolina at Charlotte and leverages decades of research into cancer-specific epitopes.